The White House is coming under pressure from some of its closest allies to name a CEO to run its health insurance marketplace.
Activist investor Carl Icahn reported a 12.63 stake in medical device maker Hologic, prompting the company to seek protection from a hostile takeover
An entrepreneur has attracted investments from four billionaires: Sam Zell, Herb Simon, David Bonderman and "one family you've never heard of."
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Keith Smith, Co-founder, Managing Partner at the Surgery Center of Oklahoma says that all funds are channeled to patient care, helping his team deliver quality healthcare and low costs.
Most robotic surgery takes place without a hitch, but a growing number of complaints and lawsuits allege complications and even deaths from Intuitive Surgical's da Vinci device.
If the critics of robotic surgery are right—that safety is an issue—how is that it was performed on 450,000 people last year? The answer may lie in one word: Marketing.
The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.
Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.
Like all computers, Intuitive Surgical's da Vinci robot can malfunction during surgery. A range of results have been reported by surgeons.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
Containing health care costs, promoting innovation and the treatment of deadly diseases are among the biggest challenges the U.S. faces, Johnson and Johnson CEO Alex Gorsky said on Thursday.
Irish drugmaker Elan has sweetened the terms on offer to shareholders under its $3.25 billion disposal plan, as it aims to stave off an approach for the company from U.S. investment firm Royalty Pharma.
A sharp and surprisingly persistent slowdown in the growth of health care costs is helping to narrow the federal deficit, leaving budget experts trying to figure out whether the trend will last.
DaVita could be a beneficiary among health care stocks from changes in the U.S. health care market, an analyst said Wednesday.
CVS Caremark is looking at changes in U.S. healthcare as an opportunity to serve more customers, whether they are picking up prescriptions, getting them through the mail or stopping by an in-house MinuteClinic for a checkup.
The managing partner of Google's venture capital, Bill Maris, says under-investment in health sciences is short-sighted.
The goal is to enable physicians and pharmaceutical companies to use complex genetic data to tailor treatment on an individual basis, according to Mike Pellini, CEO of Foundation Medical.